

**Exh. AIW-1T  
Docket UG-200568  
Witness: Amy I. White**

**BEFORE THE WASHINGTON  
UTILITIES AND TRANSPORTATION COMMISSION**

**WASHINGTON UTILITIES AND  
TRANSPORTATION COMMISSION,**

**Complainant,**

**v.**

**CASCADE NATURAL GAS  
CORPORATION,**

**Respondent.**

**DOCKET UG-200568**

**TESTIMONY OF**

**Amy I. White**

**STAFF OF  
WASHINGTON UTILITIES AND  
TRANSPORTATION COMMISSION**

***MAOP Deferral  
Restate End of Period Adjustment***

**November 19, 2020**



1 **I. INTRODUCTION**

2

3 **Q. Please state your name and business address.**

4 A. My name is Amy I. White, and my business address is 621 Woodland Square Loop  
5 SE, Lacey, Washington, 98503. My business mailing address is P.O. Box 47250,  
6 Olympia, Washington, 98504-7250. My business email address is  
7 Amy.White@utc.wa.gov.

8

9 **Q. By whom are you employed and in what capacity?**

10 A. I am employed by the Washington Utilities and Transportation Commission  
11 (Commission) as a Regulatory Analyst in the Energy Regulation Section of the  
12 Regulatory Services Division.

13

14 **Q. How long have you been employed by the Commission?**

15 A. I have been employed by the Commission since June 2007.

16

17 **Q. Please state your qualifications to provide testimony in this proceeding.**

18 A. I have a master's degree in public administration as well as a master's degree in  
19 business administration from City University of Seattle, and a bachelor's degree in  
20 accounting and business administration from the University of Washington. I  
21 attended the National Association of Regulatory Utility Commissioners' Annual  
22 Regulatory Studies Program in August 2007, the Western Utility Rate School

1 sponsored by Michigan State University in May 2008, and other sector-specific  
2 workshops, trainings, and conferences.

3  
4 **Q. Have you testified previously before the Commission?**

5 A. I previously filed testimony in Docket UW-101818 regarding Cristalina Water, LLC,  
6 in Dockets UW-110107 and UW-110220, both concerning Summit View Water  
7 Company, in Dockets UE-170485 and UG-170486, general rate cases filed by Avista  
8 Corporation, and in Docket UG-170929, a general rate case filing by Cascade  
9 Natural Gas Corporation (Cascade or Company). Most recently I drafted testimony  
10 in PacifiCorp's 2019 general rate case, Docket UE-191024, though that case was  
11 settled before testimony was filed.

12  
13 **II. SCOPE AND SUMMARY OF TESTIMONY**

14  
15 **Q. What is the scope and purpose of your testimony?**

16 A. My testimony addresses Pro Forma Adjustment P-4, MAOP Deferral Amortization,  
17 which Staff contests.

18  
19 **Q. Please summarize your recommendations.**

20 A. I recommend that the Commission order Cascade to use a new, separate ten-year  
21 amortization for each year's Maximum Allowable Operating Pressure (MAOP)  
22 investment cohort, consistent with the direction the Commission already provided

1 Cascade in Order 06 in Docket UG-170929<sup>1</sup>. The Commission should not accept  
2 Cascade's Adjustment P-4 because it amortizes MAOP investments more rapidly  
3 than the 10 years required by Order 06. Under Cascade's approach, the Company  
4 would shorten the amortization period further with each passing year.

5 Staff's Adjustment P-4 increases expense by \$800,404 before the tax impact,  
6 resulting in a decrease to net operating income of \$632,320. As compared to  
7 Cascade's Adjustment P-4, Staff's Adjustment P-4 increases the Company's net  
8 operating income by \$99,022.

9  
10 **Q. Have you prepared any exhibits in support of your testimony?**

11 A. Yes. I prepared Exhibit AIW-2 which shows Staff's calculation of Adjustment P-4,  
12 MAOP Amortization Expense.

13  
14 **III. DISCUSSION**

15  
16 **A. Contested Adjustment P-4, MAOP Deferral Amortization**

17  
18 **Q. Please provide background about Company Adjustment P-4, MAOP Deferral**  
19 **Amortization.**

20 A. The Company has implemented the MAOP Determination and Validation Plan for  
21 pipeline repair which was submitted to the commission in Docket PG-150120.

---

<sup>1</sup> *Wash. Utils. & Transp. Comm'n v. Cascade Natural Gas Corporation*, Docket UG-170929, Order 06, 18, ¶ 61 (July 20, 2018) (2017 Cascade GRC Order) .

1 Cascade was approved for deferred accounting treatment of costs in Docket UG-  
2 160787.<sup>2</sup> The Company was ordered to amortize MAOP investments using a ten-  
3 year life in Docket UG-170929.<sup>3</sup>

4  
5 **Q. What approach did Cascade take in filing its adjustment?**

6 A. The Company used one overall ten-year amortization period for all investments in  
7 the program rather than a subsequent ten-year period for each subsequent year's  
8 investment cohort. The Company's adjustment uses the first cohort's remaining  
9 amortization life of nine years to amortize the investments made in subsequent years.

10  
11 **Q. Why is Cascade's approach incorrect?**

12 A. Because the Company amortized its most recent MAOP investments using a nine-  
13 year life, even though the Company was instructed to amortize them using a ten-year  
14 life. Cascade is attempting to progressively accelerate its recovery of MAOP  
15 investments in direct violation of the ten-year life for MAOP investments that the  
16 commission ordered in Docket UG-170929.

17  
18 **Q. How could Cascade's approach to amortizing its MAOP investments incentivize  
19 the Company to delay carrying out repairs?**

20 A. It could incentivize the Company to delay investment in the MAOP safety program  
21 into the last years of the original ten-year time period to distort those years'

---

<sup>2</sup> *Wash. Utils. & Transp. Comm'n v. Cascade Natural Gas Corporation*, Docket UG-160787, Order 01, 4, ¶ 14 (November 10, 2016).

<sup>3</sup> 2017 Cascade GRC Order at 18, ¶ 61.

1 amortization expenses. If carried out to its extreme, all investments during the tenth  
2 year of the original investment cohort's life, for example, would be completely  
3 amortized *in* year ten, rather than *over* ten years. If year ten was then used as a test  
4 year in a general rate case, this distorted amortization expense would be embedded in  
5 rates, and customers would pay rates based on this distorted amount until the  
6 Company's next general rate case became effective.

7  
8 **Q. Please summarize the potential undesirable results from Cascade's approach.**

9 A. Delay of investment into the MAOP program to distort amortization expense could  
10 lead to distorted costs being embedded in rates, forcing customers to overpay.

11 Delaying repairs to distort amortization costs is also undesirable from a safety point  
12 of view, since the common good calls for potentially unsafe pipelines to be repaired  
13 as quickly as possible.

14  
15 **Q. Please describe Staff's adjustment.**

16 A. Staff's Adjustment P-4 uses a separate ten-year amortization for each year's MAOP  
17 investment cohort, consistent with the Commission's direction in Order 06 in Docket  
18 UG-170929. Exhibit AIW-2 shows the calculation. This exhibit also includes a  
19 schedule with amortization start and end dates for each year's investment.

20  
21 **Q. What effect does Staff's adjustment have?**

22 A. Staff's adjustment increases expense by \$800,404 and decreases the net operating  
23 income after tax by \$632,320.

1           **B.     Uncontested Adjustments**

2

3   **Q.     Please describe Staff’s proposed change to Restating Adjustment R-4, Restate**  
4           **Plant from Average of Monthly Averages basis to End Of Period basis.**

5   A.     The adjustment restates plant from average of monthly averages (AMA) to end of  
6           period (EOP) balances and is also impacted by Staff’s proposed capital structure and  
7           weighted cost of capital. The Company’s adjustment applies its proposed cost of  
8           capital to the EOP plant balance. The difference between the Company’s proposal  
9           and Staff’s recommendation results from the change in the cost of capital in the  
10          calculation. Staff’s restated AMA to EOP adjustment further decreases the  
11          Company’s net operating income by \$812,389, as shown in Table 1 of Staff witness  
12          Hillstead’s testimony.<sup>4</sup>

13

14   **Q.     Does Staff calculate a different return than the Company on the EOP plant**  
15           **balance?**

16   A.     Yes. Staff does not contest the Company’s method of calculating R-4, which has  
17           been made using methodology consistent with previous rate cases. Staff’s calculation  
18           applies Staff witness Parcell’s recommended weighted cost of capital of 6.93  
19           percent<sup>5</sup> to the EOP rate base. The Company’s adjustment applies its proposed  
20           weighted cost of debt to the EOP plant balance. The difference between the  
21           Company’s proposal and Staff’s recommendation results from the change in the  
22           weighted average cost of debt in the calculation. Staff’s restate AMA to EOP

---

<sup>4</sup> Hillstead, Exh. KMH-1T at 8:8.

<sup>5</sup> Parcell, Exh. DCP-1T at 2:14.



1 adjustment decreases the Company's net operating income by \$812,389, identical to  
2 the Company's calculation. Staff's calculation differs from the Company's in  
3 calculating the revenue requirement, where the Company seeks \$3,238,704 return  
4 on the EOP rate base, and Staff calculates \$3,062,419, a difference of (\$176,285),  
5 due to Staff's use of Parcell's cost of capital of 6.93 percent.

6

7 **Q. Have you prepared an exhibit related to Adjustment R-4?**

8 A. Yes. Exh. AIW-3 shows the revenue requirement effect.

9

10 **Q. Does this conclude your testimony?**

11 A. Yes.

12

13